Clinical Trials Logo

Actinic Keratosis (AK) clinical trials

View clinical trials related to Actinic Keratosis (AK).

Filter by:
  • None
  • Page 1

NCT ID: NCT03727074 Completed - Clinical trials for Actinic Keratosis (AK)

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

To compare the relative efficacy and safety and of 5-FU Cream to the marketed formulation Efudex® (5-FU) Cream, and to demonstrate the superior efficacy of the two active formulations over that of the Vehicle Control Cream, in the treatment of actinic keratosis.

NCT ID: NCT03116698 Completed - Clinical trials for Actinic Keratosis (AK)

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Start date: February 14, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.

NCT ID: NCT02406014 Completed - Clinical trials for Actinic Keratosis (AK)

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Start date: April 2015
Phase: Phase 4
Study type: Interventional

This is a phase 4, multi-centre, randomized, two group, open label, active controlled, parallel group, 17 week trial.

NCT ID: NCT01926496 Completed - Clinical trials for Actinic Keratosis (AK)

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

Start date: September 11, 2013
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream. Subjects will be randomised to treatment with ingenol mebutate or imiquimod and will receive a second treatment cycle with the same treatment if the first treatment does not clear all AKs. Subjects will be followed over a period of three year (36 months) after first treatment